David Hirsch, MD, PhD


David Hirsch is a managing director and founder of Longitude Capital. Prior to Longitude, Dr. Hirsch was a vice president of Pequot Ventures, where he worked in the life sciences practice. Prior to Pequot, he was an engagement manager at McKinsey & Company. He currently sits on the boards of Collegium Pharmaceutical (NASDAQ: COLL), Rapid Micro Biosystems and Velicept Therapeutics. He previously served on the board of Civitas Therapeutics and Precision Therapeutics. Hirsch led Longitude’s investments in Amarin and Cadence Pharmaceuticals. He has also been actively involved in Longitude’s investments in InfaCare Pharmaceuticals, Corcept Therapeutics, Horizon Pharmaceuticals, Jazz Pharmaceuticals and Sequenom.  Hirsch holds a doctorate in biology from the Massachusetts Institute of Technology, a medical doctorate from Harvard Medical School, and a bachelor’s degree in biology from The Johns Hopkins University.